MX2024002539A - Enzimas con dominios ruvc. - Google Patents
Enzimas con dominios ruvc.Info
- Publication number
- MX2024002539A MX2024002539A MX2024002539A MX2024002539A MX2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A
- Authority
- MX
- Mexico
- Prior art keywords
- enzymes
- ruvc domains
- ruvc
- domains
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237791P | 2021-08-27 | 2021-08-27 | |
| US202163245629P | 2021-09-17 | 2021-09-17 | |
| US202163252956P | 2021-10-06 | 2021-10-06 | |
| US202163282909P | 2021-11-24 | 2021-11-24 | |
| US202263316895P | 2022-03-04 | 2022-03-04 | |
| US202263319681P | 2022-03-14 | 2022-03-14 | |
| US202263322944P | 2022-03-23 | 2022-03-23 | |
| US202263369858P | 2022-07-29 | 2022-07-29 | |
| PCT/US2022/041755 WO2023028348A1 (en) | 2021-08-27 | 2022-08-29 | Enzymes with ruvc domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002539A true MX2024002539A (es) | 2024-03-19 |
Family
ID=85323459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002539A MX2024002539A (es) | 2021-08-27 | 2022-08-29 | Enzimas con dominios ruvc. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12435323B2 (enExample) |
| EP (1) | EP4392561A4 (enExample) |
| JP (1) | JP2024533940A (enExample) |
| KR (1) | KR20240049306A (enExample) |
| CN (1) | CN119452085A (enExample) |
| AU (1) | AU2022335499A1 (enExample) |
| CA (1) | CA3225082A1 (enExample) |
| MX (1) | MX2024002539A (enExample) |
| WO (1) | WO2023028348A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| CA3252595A1 (en) | 2022-05-25 | 2023-11-30 | Metagenomi Therapeutics, Inc. | LIVER ENZYME EXPRESSION SUPPLEMENTATION |
| EP4587564A2 (en) * | 2022-09-16 | 2025-07-23 | Alia Therapeutics Srl | Enqp type ii cas proteins and applications thereof |
| WO2025097031A1 (en) * | 2023-11-02 | 2025-05-08 | Metagenomi, Inc. | Compositions and methods for cell therapy |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| SG11201608701QA (en) | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| MX2017014560A (es) | 2015-05-15 | 2018-03-01 | Pioneer Hi Bred Int | Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia. |
| US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| EP3929287A3 (en) | 2015-06-18 | 2022-04-13 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| EP3390632B1 (en) | 2015-12-18 | 2025-09-10 | Danisco US Inc. | Methods and compositions for polymerase ii (pol-ii) based guide rna expression |
| MX2018010484A (es) | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| EP3426780A1 (en) | 2016-03-11 | 2019-01-16 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| EP3452499A2 (en) | 2016-05-06 | 2019-03-13 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| KR20190049887A (ko) * | 2016-09-29 | 2019-05-09 | 난트케이웨스트, 인크. | 감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포 |
| CA3038982A1 (en) | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| WO2018074979A1 (en) | 2016-10-17 | 2018-04-26 | Nanyang Technological University | Truncated crispr-cas proteins for dna targeting |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018209712A1 (en) | 2017-05-19 | 2018-11-22 | Tsinghua University | Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna |
| CN110168078B (zh) | 2017-01-06 | 2024-05-14 | 免疫生物公司 | 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞 |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| CN110892069B (zh) | 2017-03-30 | 2024-02-09 | 国立大学法人京都大学 | 基于基因组编辑的外显子跳跃诱导方法 |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| CN107164377A (zh) | 2017-06-12 | 2017-09-15 | 王小平 | 基于碱基编辑的基因敲除方法及其应用 |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| BR112020009268A2 (pt) | 2017-11-10 | 2020-11-17 | University Of Massachusetts | plataformas de distribuição de crispr direcionadas |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| AU2018383712B2 (en) | 2017-12-11 | 2025-09-04 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019161290A1 (en) | 2018-02-15 | 2019-08-22 | Sigma-Aldrich Co. Llc | Engineered cas9 systems for eukaryotic genome modification |
| KR20200124702A (ko) | 2018-02-23 | 2020-11-03 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 cas9 오르소로그 |
| CA3093919A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| EP3775213A1 (en) | 2018-04-13 | 2021-02-17 | Sigma Aldrich Co. LLC | Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins |
| WO2020041120A1 (en) | 2018-08-20 | 2020-02-27 | Massachusetts Institute Of Technology | Robotic manipulation of objects using external contacts |
| WO2020055941A1 (en) | 2018-09-13 | 2020-03-19 | Excision Biotherapeutics, Inc. | Compositions and methods for excision with single grna |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CA3116132A1 (en) | 2018-10-16 | 2020-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| KR20210116526A (ko) | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US20220220460A1 (en) | 2019-02-14 | 2022-07-14 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CN113728097A (zh) | 2019-02-14 | 2021-11-30 | 宏基因组学知识产权技术有限责任公司 | 具有ruvc结构域的酶 |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| KR20240007322A (ko) | 2019-02-14 | 2024-01-16 | 메타지노미, 인크. | Ruvc 도메인이 존재하는 효소 |
| BR112021016046A2 (pt) * | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| JP2020154564A (ja) | 2019-03-19 | 2020-09-24 | 富士通株式会社 | 学習方法、学習プログラムおよび学習装置 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220403357A1 (en) | 2019-11-12 | 2022-12-22 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| CA3177051A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| WO2021202559A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| CN116096892A (zh) | 2020-05-08 | 2023-05-09 | 宏基因组学公司 | 具有RuvC结构域的酶 |
| WO2021226369A1 (en) | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| CN112126661B (zh) | 2020-09-30 | 2022-07-22 | 上海中医药大学 | 一种高效敲除nk细胞中tigit基因的方法 |
| EP4203993A4 (en) | 2020-10-23 | 2024-10-23 | The Broad Institute, Inc. | Reprogrammable iscb nucleases and uses thereof |
| EP4259160A4 (en) * | 2020-12-14 | 2025-05-14 | Emendobio Inc. | BIALLELIC INACTIVATION OF B2M |
| KR20230134543A (ko) * | 2021-01-22 | 2023-09-21 | 메타지노미, 인크. | 신규한 조작된 뉴클레아제 및 키메라 뉴클레아제 |
| JP7877351B2 (ja) | 2021-03-19 | 2026-06-22 | メタゲノミ セラピューティクス，インク． | Ｃａｓ酵素を用いたマルチプレックス編集 |
| EP4330386A4 (en) | 2021-04-30 | 2025-05-14 | Metagenomi, Inc. | Enzymes with ruvc domains |
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| WO2023097262A1 (en) | 2021-11-24 | 2023-06-01 | Metagenomi, Inc. | Endonuclease systems |
| CA3254301A1 (en) * | 2022-03-14 | 2023-09-21 | Metagenomi Therapeutics, Inc. | MODIFIED AND CHIMERIC NUCLEASE |
-
2022
- 2022-08-29 CN CN202280062860.0A patent/CN119452085A/zh active Pending
- 2022-08-29 CA CA3225082A patent/CA3225082A1/en active Pending
- 2022-08-29 WO PCT/US2022/041755 patent/WO2023028348A1/en not_active Ceased
- 2022-08-29 EP EP22862160.3A patent/EP4392561A4/en active Pending
- 2022-08-29 AU AU2022335499A patent/AU2022335499A1/en active Pending
- 2022-08-29 KR KR1020247008513A patent/KR20240049306A/ko active Pending
- 2022-08-29 JP JP2024502432A patent/JP2024533940A/ja active Pending
- 2022-08-29 MX MX2024002539A patent/MX2024002539A/es unknown
-
2024
- 2024-02-26 US US18/586,929 patent/US12435323B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022335499A1 (en) | 2024-02-22 |
| JP2024533940A (ja) | 2024-09-18 |
| CN119452085A (zh) | 2025-02-14 |
| KR20240049306A (ko) | 2024-04-16 |
| WO2023028348A1 (en) | 2023-03-02 |
| EP4392561A4 (en) | 2025-12-24 |
| US12435323B2 (en) | 2025-10-07 |
| EP4392561A1 (en) | 2024-07-03 |
| CA3225082A1 (en) | 2023-03-02 |
| US20240200047A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009886A (es) | Enzimas con dominios ruvc. | |
| MX2022014067A (es) | Enzimas con dominios ruvc. | |
| MX2023002913A (es) | Enzimas para edicion de bases. | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| CL2021000650A1 (es) | Moduladores de la expresión de pnpla3 | |
| MX2023012606A (es) | Enzimas con dominios ruvc. | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| BR112018070133A2 (pt) | dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos | |
| BR112016003127A2 (pt) | composições e métodos para modular rna | |
| MX2015014385A (es) | Metodo para tratar trastorno de estres post-traumatico. | |
| EP4328241A3 (en) | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof | |
| CR11031A (es) | Composiciones de enzima digestiva estable | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
| EA201500943A1 (ru) | Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов | |
| BR112014017021A2 (pt) | inibidores de irak e usos dos mesmos | |
| BR112016017509A2 (pt) | composições e métodos compreendendo uma variante da enzima xilanase | |
| MX2024006257A (es) | Sistemas de endonucleasas. | |
| MX2019010759A (es) | Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas. | |
| BR112018071600A2 (pt) | métodos, composições e usos relacionados aos mesmos | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2017014213A (es) | Penicilina-g acilasas. | |
| MX2020004211A (es) | Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial. | |
| BR112018071601A2 (pt) | métodos, composições e usos relacionados aos mesmos |